Loading patent…
AssigneeStatens Seruminstitut
InventorsMorten Dziegiel, Martin Borre, Soren Jepsen, Jens Vuust, Klaus Rieneck, Annette Wind, Palle H. Jakobsen
Estimating the term…
The present invention relates to a polypeptide comprising a characteristic amino acid sequence derived from the Plasmodium falciparum antigen GLURP, a polypeptide which is recognized by an antibody raised against or reactive with a polypeptide comprising said characteristic amino acid sequence and/or an antibody reactive with native GLURP, a nucleic acid molecule (DNA-fragment) encoding said polypeptide, an expression vector carrying the nucleic acid molecule, an organism expressing said nucleic acid molecule so as to produce said polypeptide, a monoclonal antibody directed against said polypeptide, a diagnostic agent comprising said antibody or said polypeptide for use in assaying Plasmodium falciparum infection and thus diagnosing malaria, and the use of said antibody or said polypeptide for therapeutic purposes, e.g. as a component in a vaccine.
A substantially pure polypeptide comprising the amino acid sequence of a glutamate-rich polypeptide (GLURP) derived from a Plasmodium falciparum antigen ("native GLURP"), said GLURP having the amino acid sequence set forth in FIG. 8.
A substantially pure polypeptide which comprises at least one epitope reactive with an antibody which recognized the GLURP.
A fusion protein comprising the GLURP amino acid sequence set forth in FIG. 8, fused to .beta.-galactosidase.
Dependencies are inferred from the claim text.